Knowledge
of a patient's PSA (prostate-specific
antigen) is important in
a variety of clinical situations.
Access to a PSA result, within
10 minutes, in a clinic may
shorten the diagnostic pathway,
improve the patient's experience
and lead to efficiencies
in the delivery of healthcare.
PSAwatch has been designed
to be utilised in several
different clinical circumstances
•
•
•
•
•
•
Men
with LUTS (lower urinary
tract symptoms)
Suspicious DRE (digital rectal
examination)
PSA surveillance and PSA velocity
δPSA/δt
Monitoring response of prostate
cancer to therapy (hormones,
radiotherapy, brachytherapy,
cryotherapy or HIFU)
Prostate cancer screening with
age specific range
Prostate cancer “active
surveillance”
View
the PSAwatch in action
Reference
[1]
Point-of-care PSA testing.
An evaluation of PSAwatchTM.
O Karim, A Rao, M Emberton,
D Cochrane, M Partridge, P
Edwards, I Walker and I Davidson.
Prostate Cancer and Prostatic
Diseases. Click here to link
to article.
Features
•
Measures
total PSA (0.5 – 25μg/L)
•
10
minute quantitative
test
•
Immediate
result
•
Small
sample (whole blood
or plasma)
•
Capillary
(finger-prick) or venous
specimen
•
PSAwatch
is read with the Mediwatch
Bioscan
•
Internally
calibrated with positive
control
•
Equimolar
with NIBSC and European
standards
•
Individually
packaged in boxes of
20
Technical
Specification
For
more technical information
on this product please
download the data sheet.
.: coming
soon
Mediwatch UK Ltd Swift House - Cosford Lane - Rugby CV21 1QN - UK
Telephone: +44 (0) 1788 547888 - Fax: +44 (0) 1788 536434 - E-mail: info@mediwatch.com
